Detalles de la búsqueda
1.
Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.
Am J Gastroenterol
; 119(2): 306-312, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37737675
2.
Interobserver agreement of current and new proposed endoscopic scores for postoperative recurrence in Crohn's disease.
Gastrointest Endosc
; 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38462057
3.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
Dig Dis Sci
; 69(6): 2165-2174, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38594435
4.
Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease.
Int J Behav Med
; 26(4): 415-426, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31183787
5.
High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Dig Dis Sci
; 62(2): 465-472, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27933473
6.
Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study.
Inflamm Bowel Dis
; 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38666643
7.
Impact of timing of primary ileocecal resection on prognosis in patients with Crohn's disease.
BJS Open
; 7(5)2023 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772836
8.
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
Aliment Pharmacol Ther
; 57(1): 117-126, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36282200
9.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
; 8(4): 343-355, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36736339
10.
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
J Crohns Colitis
; 17(11): 1771-1780, 2023 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37310877
11.
Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West.
Inflamm Bowel Dis
; 28(Suppl 2): S16-S24, 2022 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34969091
12.
Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease.
Eur J Gastroenterol Hepatol
; 34(10): 983-992, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062493
13.
Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
J Crohns Colitis
; 15(11): 1920-1930, 2021 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909062
14.
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.
J Crohns Colitis
; 15(4): 529-539, 2021 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33079178
15.
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
Aliment Pharmacol Ther
; 52(8): 1366-1376, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32901983
16.
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Aliment Pharmacol Ther
; 52(1): 123-134, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32441396
17.
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
J Crohns Colitis
; 14(1): 33-45, 2020 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31219157
18.
Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.
Clin Pharmacol Ther
; 107(5): 1189-1199, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677154
19.
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Aliment Pharmacol Ther
; 51(9): 880-888, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32237087
20.
[Gastric perforation in Eastern European economic migrants]. / Maagperforatie bij Oost-Europese arbeidsmigranten.
Ned Tijdschr Geneeskd
; 1632019 04 11.
Artículo
en Neerlandesa
| MEDLINE | ID: mdl-31050268